Pharmaceuticals

Nanoform signs GMP manufacturing program with TargTex following formulation success

HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...

2022-02-04 15:54 3155

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...

2022-02-04 06:54 2513

Mentice publishes the company's year-end report for the period January-December 2021

STOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) * Order intake amounted to 73.7 (73.1) MSEK. * Net sales amounted to 67.7 (45.9) MSEK. * Operating income for the period before depreciation...

2022-02-03 15:37 2143

CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma

LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...

2022-02-02 11:00 2863

World's most trusted source for chemistry information, CAS, launches major biology expansion

CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...

2022-02-02 10:42 2746

New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good

TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...

2022-02-01 21:00 2133

Cytiva fuels biotech development in Australia and New Zealand

* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...

2022-02-01 07:00 2935

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com ), a Swiss biopharmaceutical company andAspen, a South African headquartered multinational pharmaceutical company announced today their partnership to  launch Tr...

2022-02-01 06:00 3136

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...

2022-02-01 05:30 2349

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vac...

2022-02-01 04:06 3356

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...

2022-01-31 19:00 1666

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...

2022-01-29 11:37 6769

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...

2022-01-29 05:28 4087

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...

2022-01-28 22:00 2824

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...

2022-01-28 21:00 2487

Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis

* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...

2022-01-28 08:10 1830

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...

2022-01-27 22:10 1842

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation toDZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metasta...

2022-01-27 21:15 3576

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2022-01-27 21:00 3448

Exyte Closes 2021 with Record Order Intake

- Order intake FY 2021 of over €8 billion, more than doubling YOY - Semiconductor and battery boom are main drivers for increased order intake - Outlook continues to be very positive STUTTGART, Germany, Jan. 27, 2022 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery ...

2022-01-27 20:53 2557
1 ... 194195196197198199200 ... 315